In addition, we evaluated the efficacy of DS-6051b using lung cancer PDX model harboring CD74-ROS1 fusion gene in vivo, and DS-6051b treatment markedly inhibited tumor growth at ≥10 mg/kg DS-6051b without significant body weight loss (Fig. 2i; Supplementary Fig. 5b). This evidence concerns the gene CD74 and lung cancer.